Treprostinil Side Effects
Medically reviewed by Drugs.com. Last updated on Jan 31, 2024.
For Healthcare Professionals
Applies to treprostinil: inhalation powder, inhalation solution, injectable solution, oral tablet extended release.
General
Oral tablets: The most frequently reported side effects were headache, diarrhea, nausea, and flushing.
Oral inhalation: The most frequently reported side effects were cough, headache, diarrhea, nausea, dizziness, throat irritation, pharyngolaryngeal pain, and flushing.
Parenteral: The most frequently reported side effects were subcutaneous infusion site pain and reaction, headache, diarrhea, nausea, jaw pain, vasodilation, edema, and hypotension.[Ref]
Local
Very common (10% or more): Infusion site pain (up to 85%), infusion site reaction (up to 83%), Infusion site bleeding/bruising (33.5%)
Frequency not reported: Induration, erythema, infusion site infection
Postmarketing reports: Subcutaneous infusion site abscess[Ref]
Gastrointestinal
Very common (10% or more): Diarrhea (up to 30%), nausea (up to 30%)
Common (1% to 10%): Abdominal discomfort, rectal hemorrhage, melena, vomiting, abdominal pain, dyspepsia
Frequency not reported: Gastrointestinal bleeding[Ref]
Nervous system
Very common (10% or more): Headache (up to 63%)
Common (1% to 10%): Syncope, paresthesia, dizziness[Ref]
Cardiovascular
Very common (10% or more): Flushing (15%), vasodilation (up to 11%)
Common (1% to 10%): Hypotension, tachycardia, palpitation, hypertension, heart failure, bradycardia, hemorrhage
Frequency not reported: Systemic blood pressure decreased, pallor, right ventricular heart failure, supraventricular tachycardia, hematoma
Postmarketing reports: Thrombophlebitis[Ref]
Dermatologic
Very common (10% or more): Rash (up to 83.1%), pruritus (up to 13.6%)
Common (1% to 10%): Contact dermatitis, sweating, ecchymosis, cellulitis
Uncommon (0.1% to 1%): Skin ulcer
Postmarketing reports: Angioedema, macular rash, popular rash[Ref]
Musculoskeletal
Very common (10% or more): Pain in extremity (14%), pain in jaw (up to 13.1%)
Common (1% to 10%): Myalgia, back pain
Uncommon (0.1% to 1%): Neck pain, arthralgia, leg cramp, muscle pain
Postmarketing reports: Bone pain, muscle spasm[Ref]
Respiratory
Very common (10% or more): Cough (54%), throat irritation/pharyngolaryngeal pain (25%)
Common (1% to 10%): Hypoxia, epistaxis, pharyngitis, dyspnea, sinusitis, pulmonary hypertension, rhinitis, hemoptysis
Uncommon (0.1% to 1%): Bronchitis
Frequency not reported: Wheezing, pneumonia[Ref]
Other
Very common (10% or more): Pain (11.9%)
Common (1% to 10%): Edema, infection, flu syndrome, asthenia, overdose, chest pain, fever, peripheral edema
Uncommon (0.1% to 1%): Viral infection, malaise
Frequency not reported: Infection, fatigue, BUN decreased, LDH decreased, bilirubin decreased, swelling arm[Ref]
Metabolic
Common (1% to 10%): Hypokalemia, anorexia, dehydration, gout[Ref]
Genitourinary
Common (1% to 10%): Urinary tract infection[Ref]
Hematologic
Common (1% to 10%): Anemia
Frequency not reported: Bleeding, thrombocytopenia, WBC decreased, RBC decreased, hemoglobin decreased, hematocrit decreased, eosinophils increased, platelet count increased[Ref]
Psychiatric
Common (1% to 10%): Insomnia, anxiety, depression
Uncommon (0.1% to 1%): Nervousness[Ref]
More about treprostinil
- Check interactions
- Compare alternatives
- Pricing & coupons
- Reviews (24)
- Latest FDA alerts (1)
- Side effects
- Dosage information
- During pregnancy
- Drug class: agents for pulmonary hypertension
- Breastfeeding
Patient resources
- Treprostinil drug information
- Treprostinil inhalation
- Treprostinil injection
- Treprostinil (Inhalation) (Advanced Reading)
- Treprostinil (Injection) (Advanced Reading)
- Treprostinil (Oral) (Advanced Reading)
Other brands
Remodulin, Orenitram, Tyvaso, Tyvaso DPI
Professional resources
Other brands
Remodulin, Orenitram, Tyvaso, Tyvaso DPI
Related treatment guides
References
1. Product Information. Remodulin (treprostinil). United Therapeutics Corporation. 2002.
2. Cerner Multum, Inc. Australian Product Information.
3. Product Information. Tyvaso (treprostinil). United Therapeutics Corporation. 2009.
4. Product Information. Orenitram (treprostinil). United Therapeutics Corporation. 2017.
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Some side effects may not be reported. You may report them to the FDA.